Journal
PLATELETS
Volume 32, Issue 6, Pages 770-778Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/09537104.2021.1925102
Keywords
Thrombopoietin; thrombopoietin receptor; platelets; megakaryocytes; signaling
Categories
Funding
- Cancer Research UK [A24593]
- German Research Foundation (Deutsche Forschungsgemeinschaft) [PI 405/15]
- National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases [K01DK127004]
Ask authors/readers for more resources
Thrombopoietin (TPO) and its receptor MPL play essential roles in platelet production and hematopoietic stem cell maintenance, with dysregulation contributing to hematological disorders; abnormalities in the TPO-MPL axis can lead to bone marrow failure or pathological myeloproliferation; recent resolution of the debate over how TPO binding activates MPL holds potential for better-targeted therapies in blood disorders.
Thrombopoietin (TPO) and its receptor, MPL, are the primary regulators of platelet production and critical for hematopoietic stem cell (HSC) maintenance. Since TPO was first cloned in 1994, the physiological and pathological roles of TPO and MPL have been well characterized, culminating in the first MPL agonists being approved for the treatment of chronic immune thrombocytopenia in 2008. Dysregulation of the TPO-MPL signaling axis contributes to the pathogenesis of hematological disorders: decreased expression or function results in severe thrombocytopenia progressing to bone marrow failure, while hyperactivation of MPL signaling, either by mutations in the receptor or associated Janus kinase 2 (JAK2), results in pathological myeloproliferation. Despite its importance, it was only recently that the long-running debate over the mechanism by which TPO binding activates MPL has been resolved. This review will cover key aspects of TPO and MPL structure and function and their importance in receptor activation, discuss how these are altered in hematological disorders and consider how a greater understanding could lead to the development of better-targeted and more efficacious therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available